Farhan Fazal, Nitin Gupta, Manish Soneja, D K Mitra, G Satpathy, S K Panda, P K Chaturvedi, Naval K Vikram, R M Pandey, Naveet Wig
{"title":"危重患者继发性噬血细胞性淋巴组织细胞增多症的临床概况、治疗和结局:一项前瞻性观察研究。","authors":"Farhan Fazal, Nitin Gupta, Manish Soneja, D K Mitra, G Satpathy, S K Panda, P K Chaturvedi, Naval K Vikram, R M Pandey, Naveet Wig","doi":"10.5005/jp-journals-10071-24136","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The objective of the study was to evaluate the clinical profile and outcome of patients with secondary hemophagocytic lymphohistiocytosis (HLH) in critically ill patients.</p><p><strong>Materials and methods: </strong>A prospective observational study was conducted where critically ill adult patients presenting with fever and bicytopenia were evaluated according to the HLH-2004 diagnostic criteria for the presence of secondary HLH. The underlying trigger, clinical profile, treatment, and outcome of patients with HLH were analyzed.</p><p><strong>Results: </strong>Of the 76 critically ill patients with fever and bicytopenia, 33 (43%) patients were diagnosed with HLH. The following triggers for HLH were identified: bacterial infections (23%), fungal infections (10%), viral infections (10%), parasitic infections (10%), autoimmune diseases (13%), and malignancy (8%). A total of 78% of the HLH cases received steroids, but the use of steroids was not associated with improvement in mortality.</p><p><strong>Conclusion: </strong>There is a high prevalence of HLH in patients presenting with fever and bicytopenia in critically ill adult patients. Infections were identified as the most common trigger of HLH.</p><p><strong>How to cite this article: </strong>Fazal F, Gupta N, Soneja M, Mitra DK, Satpathy G, Panda SK, <i>et al</i>. Clinical Profile, Treatment, and Outcome of Patients with Secondary Hemophagocytic Lymphohistiocytosis in Critically Ill Patients: A Prospective Observational Study. Indian J Crit Care Med 2022;26(5):564-567.</p>","PeriodicalId":520643,"journal":{"name":"Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine","volume":" ","pages":"564-567"},"PeriodicalIF":1.5000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/f0/ijccm-26-564.PMC9160626.pdf","citationCount":"1","resultStr":"{\"title\":\"Clinical Profile, Treatment, and Outcome of Patients with Secondary Hemophagocytic Lymphohistiocytosis in Critically Ill Patients: A Prospective Observational Study.\",\"authors\":\"Farhan Fazal, Nitin Gupta, Manish Soneja, D K Mitra, G Satpathy, S K Panda, P K Chaturvedi, Naval K Vikram, R M Pandey, Naveet Wig\",\"doi\":\"10.5005/jp-journals-10071-24136\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The objective of the study was to evaluate the clinical profile and outcome of patients with secondary hemophagocytic lymphohistiocytosis (HLH) in critically ill patients.</p><p><strong>Materials and methods: </strong>A prospective observational study was conducted where critically ill adult patients presenting with fever and bicytopenia were evaluated according to the HLH-2004 diagnostic criteria for the presence of secondary HLH. The underlying trigger, clinical profile, treatment, and outcome of patients with HLH were analyzed.</p><p><strong>Results: </strong>Of the 76 critically ill patients with fever and bicytopenia, 33 (43%) patients were diagnosed with HLH. The following triggers for HLH were identified: bacterial infections (23%), fungal infections (10%), viral infections (10%), parasitic infections (10%), autoimmune diseases (13%), and malignancy (8%). A total of 78% of the HLH cases received steroids, but the use of steroids was not associated with improvement in mortality.</p><p><strong>Conclusion: </strong>There is a high prevalence of HLH in patients presenting with fever and bicytopenia in critically ill adult patients. Infections were identified as the most common trigger of HLH.</p><p><strong>How to cite this article: </strong>Fazal F, Gupta N, Soneja M, Mitra DK, Satpathy G, Panda SK, <i>et al</i>. Clinical Profile, Treatment, and Outcome of Patients with Secondary Hemophagocytic Lymphohistiocytosis in Critically Ill Patients: A Prospective Observational Study. Indian J Crit Care Med 2022;26(5):564-567.</p>\",\"PeriodicalId\":520643,\"journal\":{\"name\":\"Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine\",\"volume\":\" \",\"pages\":\"564-567\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2022-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/f0/ijccm-26-564.PMC9160626.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5005/jp-journals-10071-24136\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10071-24136","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
简介:本研究的目的是评估危重患者继发性噬血细胞性淋巴组织细胞增多症(HLH)的临床概况和预后。材料和方法:根据HLH-2004诊断标准对以发热和双氧体减少症为表现的危重成人患者进行了前瞻性观察研究。分析了HLH患者的潜在诱因、临床特征、治疗和结果。结果:76例发热伴双氧体减少的危重患者中,33例(43%)诊断为HLH。确定了以下触发HLH的因素:细菌感染(23%)、真菌感染(10%)、病毒感染(10%)、寄生虫感染(10%)、自身免疫性疾病(13%)和恶性肿瘤(8%)。总共78%的HLH病例接受了类固醇治疗,但类固醇的使用与死亡率的改善无关。结论:成人危重患者中以发热和双氧体减少症为表现的HLH患病率较高。感染被认为是HLH最常见的触发因素。本文出处:Fazal F, Gupta N, Soneja M, Mitra DK, Satpathy G, Panda SK等。危重患者继发性噬血细胞性淋巴组织细胞增多症的临床概况、治疗和结局:一项前瞻性观察研究。中华检验医学杂志;2009;26(5):564-567。
Clinical Profile, Treatment, and Outcome of Patients with Secondary Hemophagocytic Lymphohistiocytosis in Critically Ill Patients: A Prospective Observational Study.
Introduction: The objective of the study was to evaluate the clinical profile and outcome of patients with secondary hemophagocytic lymphohistiocytosis (HLH) in critically ill patients.
Materials and methods: A prospective observational study was conducted where critically ill adult patients presenting with fever and bicytopenia were evaluated according to the HLH-2004 diagnostic criteria for the presence of secondary HLH. The underlying trigger, clinical profile, treatment, and outcome of patients with HLH were analyzed.
Results: Of the 76 critically ill patients with fever and bicytopenia, 33 (43%) patients were diagnosed with HLH. The following triggers for HLH were identified: bacterial infections (23%), fungal infections (10%), viral infections (10%), parasitic infections (10%), autoimmune diseases (13%), and malignancy (8%). A total of 78% of the HLH cases received steroids, but the use of steroids was not associated with improvement in mortality.
Conclusion: There is a high prevalence of HLH in patients presenting with fever and bicytopenia in critically ill adult patients. Infections were identified as the most common trigger of HLH.
How to cite this article: Fazal F, Gupta N, Soneja M, Mitra DK, Satpathy G, Panda SK, et al. Clinical Profile, Treatment, and Outcome of Patients with Secondary Hemophagocytic Lymphohistiocytosis in Critically Ill Patients: A Prospective Observational Study. Indian J Crit Care Med 2022;26(5):564-567.